4H-thieno[2,3-c]pyrrole | 444-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 4H-thieno[2,3-c]pyrrole
• CAS: 444-18-8
• 化学式: C₆H₅NS
• 分子量: 123.178
• InChiKey: FDQPDKCJIRJYBF-UHFFFAOYSA-N

物化性质

• 沸点：
  240.8±29.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4H-thieno[2,3-c]pyrrole 在 silica gel 作用下， 生成 5H-噻吩并[2,3-c]吡咯
  参考文献：
  名称：

  5- H-噻吩并[2,3- c ]吡咯的合成

  摘要：

  通过新型的膦亚胺-亚烷基丙二酸酯环化反应合成了5 H-噻吩并[2,3- c ]吡咯（4）。

  DOI：

  10.1039/c39860000310
• 作为产物：
  描述：

  2-((3-(溴甲基)噻吩-2-基)亚甲基)丙二酸二乙酯 在 sodium azide 、 水 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 2.5h， 生成 4H-thieno[2,3-c]pyrrole
  参考文献：
  名称：

  5- H-噻吩并[2,3- c ]吡咯的合成

  摘要：

  通过新型的膦亚胺-亚烷基丙二酸酯环化反应合成了5 H-噻吩并[2,3- c ]吡咯（4）。

  DOI：

  10.1039/c39860000310

文献信息

• Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239838A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了包括公式I或其药学上可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备方法。本文所描述的抑制剂靶向因子D并在替代补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少补体过度激活，该过度激活已与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP2762476A1

  公开（公告）日：2014-08-06

  The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally Ra-substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally Ra-substituted C1-C8 alkyl group, an optionally Ra-substituted C2-C6 alkenyl group, an optionally Ra-substituted C2-C6 alkynyl group, an optionally Rb-substituted C3-C10 cycloalkyl group, an optionally Rb-substituted C6-C14 aromatic hydrocarbon group, an optionally Rb-substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally Rb-substituted 4-to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally Ra-substituted C1-C6 alkyl group; and B represents an optionally Rc-substituted unsaturated heterocyclic group).

  本发明提供了由下通式（I）代表的化合物或其盐，该化合物具有抑制 Syk 的作用（式中 R1 代表氢原子或任选 Ra 取代的 C1-C6 烷基；A代表氢原子、任选Ra取代的C1-C8烷基、任选Ra取代的C2-C6烯基、任选Ra取代的C2-C6炔基、任选Rb取代的C3-C10环烷基、任选Rb取代的C6-C14芳烃基、任选 Rb 取代的 4 至 10 元不饱和杂环基团，或任选 Rb 取代的 4 至 10 元饱和杂环基团，或任选与 R1 及其键合的氮原子一起形成 4 至 10 元不饱和杂环或 4 至 10 元饱和杂环；R2 代表氢原子或任选 Ra 取代的 C1-C6 烷基；以及 B 代表任选 Rc 取代的不饱和杂环基团）。
• SHA, CHIN-KANG;TSOU, CHIU-PENG, J. CHEM. SOC. CHEM. COMMUN., 1986, N 4, 310-311
  作者：SHA, CHIN-KANG、TSOU, CHIU-PENG

  DOI：——

  日期：——
• COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20160361329A1

  公开（公告）日：2016-12-15

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.
• Compounds for the Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170056428A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.